Fluorescence guided surgery and tracer-dose, fact or fiction?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin : Springer-Verlag Berlin, 2002-
    • Subject Terms:
      Neoplasms/*diagnostic imaging ; Neoplasms/*surgery ; Optical Imaging/*methods ; Sentinel Lymph Node/*diagnostic imaging ; Surgery, Computer-Assisted/*methods ; Technetium Tc 99m Aggregated Albumin/*pharmacokinetics; Humans ; Neoplasms/metabolism ; Radiopharmaceuticals/pharmacokinetics ; Reproducibility of Results ; Sensitivity and Specificity ; Sentinel Lymph Node/metabolism ; Sentinel Lymph Node/surgery
    • Abstract:
      Introduction: Fluorescence guidance is an upcoming methodology to improve surgical accuracy. Challenging herein is the identification of the minimum dose at which the tracer can be detected with a clinical-grade fluorescence camera. Using a hybrid tracer such as indocyanine green (ICG)-(99m)Tc-nanocolloid, it has become possible to determine the accumulation of tracer and correlate this to intraoperative fluorescence-based identification rates. In the current study, we determined the lower detection limit of tracer at which intraoperative fluorescence guidance was still feasible.
      Methods: Size exclusion chromatography (SEC) provided a laboratory set-up to analyze the chemical content and to simulate the migratory behavior of ICG-nanocolloid in tissue. Tracer accumulation and intraoperative fluorescence detection findings were derived from a retrospective analysis of 20 head-and-neck melanoma patients, 40 penile and 20 prostate cancer patients scheduled for sentinel node (SN) biopsy using ICG-(99m)Tc-nanocolloid. In these patients, following tracer injection, single photon emission computed tomography fused with computed tomography (SPECT/CT) was used to identify the SN(s). The percentage injected dose (% ID), the amount of ICG (in nmol), and the concentration of ICG in the SNs (in μM) was assessed for SNs detected on SPECT/CT and correlated with the intraoperative fluorescence imaging findings.
      Results: SEC determined that in the hybrid tracer formulation, 41 % (standard deviation: 12 %) of ICG was present in nanocolloid-bound form. In the SNs detected using fluorescence guidance a median of 0.88 % ID was present, compared to a median of 0.25 % ID in the non-fluorescent SNs (p-value < 0.001). The % ID values could be correlated to the amount ICG in a SN (range: 0.003-10.8 nmol) and the concentration of ICG in a SN (range: 0.006-64.6 μM).
      Discussion: The ability to provide intraoperative fluorescence guidance is dependent on the amount and concentration of the fluorescent dye accumulated in the lesion(s) of interest. Our findings indicate that intraoperative fluorescence detection with ICG is possible above a μM concentration.
    • References:
      Eur Urol. 2014 Jun;65(6):1162-8. (PMID: 24289911)
      Br J Radiol. 2009 Aug;82(980):617-25. (PMID: 19153188)
      J Nucl Med. 2014 Jan;55(1):95-8. (PMID: 24078721)
      Eur Urol. 2014 Jun;65(6):1169-70. (PMID: 24411990)
      J Biomed Opt. 2011 Jan-Feb;16(1):016004. (PMID: 21280910)
      Eur Urol. 2014 Dec;66(6):991-8. (PMID: 25092539)
      Perspect Clin Res. 2010 Apr;1(2):61-3. (PMID: 21829784)
      J Nucl Med. 2011 Apr;52(4):551-4. (PMID: 21421720)
      Radiology. 2015 May;275(2):521-9. (PMID: 25521776)
      Nat Med. 2015 Aug;21(8):955-61. (PMID: 26168295)
      Sci Rep. 2015 Jun 29;5:10169. (PMID: 26120042)
      Biomaterials. 2012 Jan;33(3):867-75. (PMID: 22024362)
      Chem Rev. 2000 Jun 14;100(6):1973-2012. (PMID: 11749281)
      Cancer. 2011 Nov 1;117(21):4812-22. (PMID: 21484779)
      J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):55-64. (PMID: 10410927)
      Eur Urol. 2014 Mar;65(3):600-9. (PMID: 24355132)
      Head Neck. 2007 Feb;29(2):95-103. (PMID: 17120312)
      J Nucl Med. 2015 Mar;56(3):410-6. (PMID: 25698782)
      Radiology. 2015 Jul;276(1):12-29. (PMID: 26101919)
      Br J Surg. 2012 Oct;99(10):1345-51. (PMID: 22961511)
      Nat Med. 2011 Sep 18;17(10):1315-9. (PMID: 21926976)
      Clin Radiol. 2000 Feb;55(2):124-30. (PMID: 10657158)
      J Biomed Opt. 2013 Feb;18(2):20502. (PMID: 23334715)
      Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1328-34. (PMID: 20306033)
      Radiology. 1995 Feb;194(2):349-55. (PMID: 7824709)
      J Am Coll Radiol. 2008 Apr;5(4):579-84. (PMID: 18359446)
      J Nucl Med. 2003 Apr;44(4):570-82. (PMID: 12679402)
    • Contributed Indexing:
      Keywords: Fluorescence-guided surgery; Microdosing; Multimodal; SPECT/CT; Sentinel node
    • Accession Number:
      0 (Radiopharmaceuticals)
      0 (Technetium Tc 99m Aggregated Albumin)
      0 (technetium Tc 99m nanocolloid)
    • Publication Date:
      Date Created: 20160330 Date Completed: 20170222 Latest Revision: 20210409
    • Publication Date:
      20240104
    • Accession Number:
      PMC4969335
    • Accession Number:
      10.1007/s00259-016-3372-y
    • Accession Number:
      27020580